Skip to main content
AstraZeneca PLC logo

AstraZeneca PLC — Investor Relations & Filings

Ticker · AZN ISIN · GB0009895292 LEI · PY6ZZQWO2IZFZC3IOL08 IL Manufacturing
Open in API
Filings indexed 3,304 across all filing types
Latest filing 2024-11-12 Regulatory Filings
Country GB United Kingdom
Listing IL AZN

About AstraZeneca PLC

https://www.astrazeneca.com/

AstraZeneca PLC is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines. The company's portfolio is concentrated on several main therapy areas, including Oncology; Cardiovascular, Renal & Metabolism; and Respiratory & Immunology. AstraZeneca is committed to advancing healthcare through a robust research and development pipeline, aiming to deliver innovative medicines that address significant unmet medical needs for millions of patients worldwide. The company leverages scientific innovation to transform the future of healthcare and improve patient outcomes.

Recent filings

Filing Released Lang Actions
KOMET Phase III trial met primary endpoint
Regulatory Filings Classification · 1% confidence The document begins with 'RNS Number : 7968L' and contains standard regulatory boilerplate language from RNS (the news service of the London Stock Exchange), including references to the Financial Conduct Authority. The content itself is an announcement detailing positive Phase III trial results (KOMET trial) for the drug Koselugo in adults with NF1. This type of announcement, which disseminates material, non-public information via an official regulatory news service, fits best under the general 'Regulatory Filings' category (RNS), as it is not a specific financial report (like 10-K or IR), a management discussion (MDA), or an earnings release (ER). It is a broad regulatory news update.
2024-11-12 English
9M and Q3 2024 Results
Interim / Quarterly Report Classification · 1% confidence The document is an official '9M and Q3 2024 results' announcement from AstraZeneca PLC. It contains detailed financial tables (Revenue, EPS, Operating Margin), management commentary, guidance updates, and pipeline milestones. It is a comprehensive financial report for a period shorter than a full fiscal year (9 months and 3rd quarter), fitting the definition of an Interim/Quarterly Report (IR). 9M 2024
2024-11-12 English
Dato-DXd new BLA submitted, NSQ BLA withdrawn
Regulatory Filings Classification · 1% confidence The document is identified by the RNS Number (7933L) and the date stamp (12 November 2024), indicating it is a regulatory announcement disseminated via the Regulatory News Service (RNS). The content describes a specific corporate action: the submission of a new Biologics License Application (BLA) and the voluntary withdrawal of a previous BLA to the US FDA concerning a drug (datopotamab deruxtecan) for lung cancer. This type of announcement, which details regulatory submissions, clinical trial updates, and corporate strategy without being a full financial report (like 10-K or IR) or a transcript, fits best under the general category for regulatory announcements that are not covered by more specific codes like DIV or DIRS. Since it is a formal, time-sensitive regulatory update, 'RNS' (Regulatory Filings) is the most appropriate classification, as it serves as the general regulatory announcement fallback.
2024-11-12 English
TEZSPIRE NASAL POLYPS TRIAL MET PRIMARY ENDPOINTS
Foreign Filer Report
2024-11-08 English
Tezspire nasal polyps trial met primary endpoints
Regulatory Filings Classification · 1% confidence The document is an announcement from AstraZeneca PLC, dated November 8, 2024, disseminated via RNS (Regulatory News Service). The content details positive results from the Phase III WAYPOINT trial for the drug Tezspire in treating chronic rhinosinusitis with nasal polyps (CRSwNP). It includes quotes from investigators and company executives, summarizes the trial endpoints, and notes that full results will be shared with regulatory authorities and the scientific community at an upcoming meeting. This format—a press release announcing clinical trial data and regulatory milestones—is characteristic of a general regulatory announcement, often categorized under RNS, especially since it is not a full financial report (10-K, IR), a specific management change (MANG), or a formal earnings release (ER). Given the source (RNS Number) and the nature of the announcement (clinical trial update), RNS is the most appropriate general regulatory filing category.
2024-11-08 English
AZN share price movement
Regulatory Filings Classification · 1% confidence The document begins with 'RNS Number : 0561L' and contains boilerplate text referencing 'RNS, the news service of the London Stock Exchange' and compliance with the Financial Conduct Authority. This strongly indicates a regulatory announcement disseminated via the RNS system. The content itself is a brief statement addressing media speculation regarding operations in China, which is a general corporate update that doesn't fit specific categories like ER, 10-K, or DIV. Given its nature as a general, non-specific regulatory disclosure distributed through the RNS platform, the most appropriate classification is the general regulatory filing fallback category.
2024-11-05 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.